Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy

Dorit Verhoeven; Arie Jan Stoppelenburg; Friederike Meyer-Wentrup; Marianne Boes

doi:10.1016/j.clim.2018.02.007

Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy

Dorit Verhoeven, Arie Jan Stoppelenburg, Friederike Meyer-Wentrup, Marianne Boes

Research output: Contribution to journal › Review article › peer-review

1 Downloads (Pure)

Abstract

Primary immunodeficiency disorders (PIDs) convey increased susceptibility to infections and sometimes to malignancies, particularly lymphomas. Such cancer development can be contributed by immune impairments resulting in weakened immunological surveillance against (pre)malignant cells and oncogenic viruses. Molecular defects in PID-patients are therefore being clarified, identifying new targets for innovative immunotherapy. Particularly pediatric cancers are being scrutinized, where over one-third of cancer-related deaths are accounted for by leukemia and lymphomas. Here we review how immunopathogenic mechanisms of several PIDs might associate with lymphoma development. We furthermore delineate existing immunotherapy strategies in adults for potential therapeutic application in childhood leukemia and lymphomas.

Original language	English
Pages (from-to)	22-31
Number of pages	10
Journal	Clinical Immunology
Volume	190
DOIs	https://doi.org/10.1016/j.clim.2018.02.007
Publication status	Published - 1 May 2018

Access to Document

10.1016/j.clim.2018.02.007

IncreasedFinal published version, 1.02 MB

Cite this

@article{c126fffa868d4d0db734ae1d43bd5b2d,

title = "Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy",

abstract = "Primary immunodeficiency disorders (PIDs) convey increased susceptibility to infections and sometimes to malignancies, particularly lymphomas. Such cancer development can be contributed by immune impairments resulting in weakened immunological surveillance against (pre)malignant cells and oncogenic viruses. Molecular defects in PID-patients are therefore being clarified, identifying new targets for innovative immunotherapy. Particularly pediatric cancers are being scrutinized, where over one-third of cancer-related deaths are accounted for by leukemia and lymphomas. Here we review how immunopathogenic mechanisms of several PIDs might associate with lymphoma development. We furthermore delineate existing immunotherapy strategies in adults for potential therapeutic application in childhood leukemia and lymphomas.",

author = "Dorit Verhoeven and Stoppelenburg, {Arie Jan} and Friederike Meyer-Wentrup and Marianne Boes",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = may,

day = "1",

doi = "10.1016/j.clim.2018.02.007",

language = "English",

volume = "190",

pages = "22--31",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Increased risk of hematologic malignancies in primary immunodeficiency disorders

T2 - opportunities for immunotherapy

AU - Verhoeven, Dorit

AU - Stoppelenburg, Arie Jan

AU - Meyer-Wentrup, Friederike

AU - Boes, Marianne

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Primary immunodeficiency disorders (PIDs) convey increased susceptibility to infections and sometimes to malignancies, particularly lymphomas. Such cancer development can be contributed by immune impairments resulting in weakened immunological surveillance against (pre)malignant cells and oncogenic viruses. Molecular defects in PID-patients are therefore being clarified, identifying new targets for innovative immunotherapy. Particularly pediatric cancers are being scrutinized, where over one-third of cancer-related deaths are accounted for by leukemia and lymphomas. Here we review how immunopathogenic mechanisms of several PIDs might associate with lymphoma development. We furthermore delineate existing immunotherapy strategies in adults for potential therapeutic application in childhood leukemia and lymphomas.

AB - Primary immunodeficiency disorders (PIDs) convey increased susceptibility to infections and sometimes to malignancies, particularly lymphomas. Such cancer development can be contributed by immune impairments resulting in weakened immunological surveillance against (pre)malignant cells and oncogenic viruses. Molecular defects in PID-patients are therefore being clarified, identifying new targets for innovative immunotherapy. Particularly pediatric cancers are being scrutinized, where over one-third of cancer-related deaths are accounted for by leukemia and lymphomas. Here we review how immunopathogenic mechanisms of several PIDs might associate with lymphoma development. We furthermore delineate existing immunotherapy strategies in adults for potential therapeutic application in childhood leukemia and lymphomas.

U2 - 10.1016/j.clim.2018.02.007

DO - 10.1016/j.clim.2018.02.007

M3 - Review article

C2 - 29499421

SN - 1521-6616

VL - 190

SP - 22

EP - 31

JO - Clinical Immunology

JF - Clinical Immunology

ER -

Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy

Abstract

Access to Document

Fingerprint

Cite this